Abstract
In December, 2020, Israel initiated a national campaign to vaccinate its population with Pfizer–BioNTech's mRNA COVID-19 vaccine BNT162b2 (tozinameran). Israel's Ministry of Health recommended a two-dose schedule with a 21-day interval between doses. Israel delivered more than 10 million doses within 4 months; by April 19, 2021, 54% of the entire population of 9·1 million people, and 88% of people aged 50 years or older, had received two doses.1 Factors contributing to Israel's rapid roll-out include its small geographical and population sizes; advanced information technology that allowed prioritisation, allocation, and documentation of vaccines for eligible individuals; effective cooperation between government and community-based health funds, which were charged with providing vaccines to those they insured; and experience in rapid large-scale emergency responses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
